FY2025 Earnings Estimate for WVE Issued By Cantor Fitzgerald

Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Wave Life Sciences in a research note issued to investors on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse forecasts that the company will post earnings per share of ($1.09) for the year. Cantor Fitzgerald has a "Overweight" rating and a $10.00 price target on the stock. The consensus estimate for Wave Life Sciences' current full-year earnings is ($1.14) per share.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last released its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.17) by $0.34. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The business had revenue of $83.75 million during the quarter, compared to the consensus estimate of $25.60 million.

A number of other equities analysts have also recently commented on the company. StockNews.com raised Wave Life Sciences from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Jefferies Financial Group assumed coverage on Wave Life Sciences in a research note on Tuesday, February 25th. They issued a "buy" rating and a $26.00 price objective for the company. HC Wainwright reiterated a "buy" rating and issued a $22.00 price objective on shares of Wave Life Sciences in a research note on Wednesday, March 26th. Finally, Wedbush started coverage on shares of Wave Life Sciences in a report on Tuesday, April 8th. They issued an "outperform" rating and a $18.00 target price on the stock. Two investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $21.17.

Wave Life Sciences Stock Down 13.9 %

Shares of WVE traded down $1.08 during trading hours on Thursday, reaching $6.66. 1,097,029 shares of the company traded hands, compared to its average volume of 1,248,401. The stock has a market capitalization of $1.03 billion, a P/E ratio of -6.00 and a beta of -0.91. The business has a fifty day moving average price of $8.10 and a 200-day moving average price of $11.36. Wave Life Sciences has a 12-month low of $4.25 and a 12-month high of $16.74.

Insider Activity at Wave Life Sciences

In other news, Director Christian O. Henry sold 10,500 shares of Wave Life Sciences stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total transaction of $102,585.00. Following the sale, the director now directly owns 16,115 shares in the company, valued at $157,443.55. The trade was a 39.45 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Paul Bolno sold 169,025 shares of the company's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the sale, the chief executive officer now owns 338,351 shares in the company, valued at $3,238,019.07. The trade was a 33.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. bought a new stake in shares of Wave Life Sciences in the 4th quarter worth approximately $40,000. Quarry LP purchased a new position in shares of Wave Life Sciences during the 4th quarter valued at $62,000. KBC Group NV purchased a new stake in shares of Wave Life Sciences during the fourth quarter worth about $67,000. Summit Investment Advisors Inc. lifted its holdings in shares of Wave Life Sciences by 31.5% in the fourth quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company's stock worth $119,000 after buying an additional 2,308 shares in the last quarter. Finally, Westwood Wealth Management bought a new position in shares of Wave Life Sciences during the 4th quarter valued at approximately $124,000. Hedge funds and other institutional investors own 89.73% of the company's stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.